SEC Form 4 · accession 0001209191-16-135285

SURMODICS INC · SRDX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Senior VP & GM, Med Dev

Period of report

Aug 1, 2016

Accepted (ET)

Aug 3, 2016 · 5:42 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000924717

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Aug 1, 2016	M	12,500	$24.30	A	35,531	D
Common Stock^F2	Aug 1, 2016	S	7,500	$27.0881	D	28,031	D
Common Stock^F3	Aug 1, 2016	S	5,000	$27.0732	D	23,031	D
Common Stock	holding	—	—		—	800	I	By IRA

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F4	$24.30	Aug 1, 2016	M	12,500	D	—	Sep 21, 2016	Common Stock	12,500	5,783	D

F1Exercise of reporting person's stock options of which shares were sold to pay the exercise price, to cover withholding taxes, and to pay broker fees and commissions, pursuant to a broker-assisted cashless exercise and sale.
F2Reflects the weighted average price of 7,500 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on August 1, 2016 with sale prices ranging from $26.99 to $27.40 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3Reflects the weighted average price of 5,000 shares of common stock of Surmodics,Inc. sold by the reporting person in multiple transactions on August 1, 2016 with sale prices ranging from $27.05 to $27.12 per share. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4This option is fully vested.